Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a medical and cosmetic cannabis products and treatment firm with operations in Latin America & Europe has announced the grand opening of its fourth Zerenia medical cannabis clinic in Bogotá’s Plaza Central shopping center. The 4,000 square foot facility features 11 patient rooms and according to Khiron, can handle 40,000 patient consultations per year.
“We are very excited about this new Zerenia format and our ability to treat more patients and create closer relationships with insurance companies in Colombia. Our Zerenia clinic network now has more than 13 locations in Colombia, Peru, and the UK, and we will soon open new locations worldwide. Our unique strategy has allowed us to grow medical cannabis sales by more than 900% in Colombia in 2021, increasing patient conversion and retention rates,” said Khiron CEO Álvaro Torres.
“The selection of this new location follows a deep desire to be closer to our patients and offer insurance companies better access for their patients while maintaining the service standards that are making Zerenia a leading global medical cannabis clinic network. Now that the Colombian Government has mandated medical cannabis to be covered by all insurance companies, we believe this new location strategy will continue to drive great growth and profitability for Khiron and will continue to allow us to improve the quality of life of more patients.”
Khiron retains investor relations firm
Khiron also announced that subject to the approval of the TSX Venture Exchange, it has retained Arrowhead Business and Investment Decisions, LLC, a US-based investor relations firm which is headquartered in New York City and was established in 2008. For the initial six-month term, Arrowhead will be paid $50,000 USD. Khiron said in a written statement that Arrowhead is not related to the company and has no interest, directly or indirectly, in Khiron or its securities.